Carerx Corporation · TSX:CRRX
Carerx — Q3 2021 Earnings Presentation
15 slides from Carerx's earnings presentation, Nov 10, 2021
Slide 1: Q3 2021 Earnings Call
Q3 2021 Earnings Call November 10, 2021
Slide 2: Forward Looking Statements
Forward Looking Statements Certain of the statements contained in this presentation are "forward looking information within the meaning of applicable Canadian securities legislation. Forward looking information includes, but is not limited to, business strategy, plans and other expectations, beliefs
Slide 3: David Murphy, President & Chief Executive Officer
David Murphy President & Chief Executive Officer 3
Slide 4: Q3 2021 Continued strong growth in revenue and Adjusted EBITDA
Q3 2021 Continued strong growth in revenue and Adjusted EBITDA + Initial contribution from Medical Pharmacies LTC Pharmacy Business + Accelerated organic growth + Acquisitions contributing in line with expectations 4
Slide 5: Q3 2021 Financial Highlights
Q3 2021 Financial Highlights From Continuing Operations • Average beds serviced of 81,816: +66% vs Q3/20 • Growth driven by SmartMeds and Rexall (+/- compared to Q3 2020) acquisitions (completed Q2/21) • Partial quarter contribution from Medical Q3 2021 Pharmacies LTC business (millions) • Adjusted
Slide 6: Medical Pharmacies: Our Largest & Most Significant Acquisition to Date
Medical Pharmacies: Our • Purchase Price: Largest & Most Significant • $70 M cash • 550,359 CareRx common shares Acquisition to Date • Financing: August 23, 2021: Completed Acquisition of • $63.3 M private placement LTC Division of Medical Pharmacies • $39 M incremental debt (and • Added ~36,000 bed
Slide 7: Successful Execution of Our Growth Strategy
Successful Execution of Our Growth Strategy Ave. Beds Serviced Revenue Adj. EBITDA Revenue Adj. EBITDA (000s) (from continuing ops) (from continuing ops) (from continuing ops) (from continuing ops) ($ millions) ($ millions) ($ millions) ($ millions) 81.8 71.3 165.8 15.3 115.8 49.3 45.6 6.9 89.1 92.4
Slide 8: Other Highlights
Other Highlights Expanded existing contract with Ontario-based seniors home operator • Expected to add approximately 1,500 new retirement and long- term care residents in 19 seniors housing communities • Onboarding has been completed during Q4 2021 • All beds to be serviced through existing infrastr
Slide 9: Andrew Mok, Chief Financial Officer
Andrew Mok Chief Financial Officer 9
Slide 10: Q3 2021 Financial Results | Revenue
Q3 2021 Financial Results | Revenue (millions) • 56% year-over-year growth • Growth driven by SmartMeds and 80 $71.3 Rexall acquisitions (completed 70 Q2/21) 60 • SmartMeds and Rexall 50 $45.6 contributions in line with expectations 40 • Partial quarter contribution from 30 Medical Pharmacies LTC Bu
Slide 11: Q3 2021 Financial Results | Adjusted EBITDA
Q3 2021 Financial Results | Adjusted EBITDA • 78% year-over-year growth • Includes quarterly contribution of >$3.0 M in (millions) annualized cost savings synergies from Remedy’s acquisition 8 • Growth driven by SmartMeds and Rexall $6.9 7 acquisitions (completed Q2/21) 6 • SmartMeds and Rexall cont
Slide 12: Balance Sheet
Balance Sheet • Received funds under previously completed private placements of subscription receipts for total gross proceeds of $63.3 M (issued 12,524,880 common shares) (millions except ratio) • Entered into amended and restated credit agreement with senior lender to refinance At Sept. 30/21 exis
Slide 13: David Murphy, President & Chief Executive Officer
David Murphy President & Chief Executive Officer 13
Slide 14: A New Baseline for Continued Growth
A New Baseline for >96,0001 beds 23% Continued Growth • Positioned to benefit from increased scale and enhanced capabilities 77% • Experiencing accelerated organic growth • Significantly strengthened position as a Market Opportunity via natural consolidator in a highly fragmented Organic Growth & Ac
Slide 15: Questions
Questions Visit our website at www.carerx.ca | Follow @CareRx on Twitter